Bristol-Myers Squibb Co (BMY) Position Raised by Norinchukin Bank The

Norinchukin Bank The increased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 234,017 shares of the biopharmaceutical company’s stock after purchasing an additional 19,461 shares during the period. Norinchukin Bank The’s holdings in Bristol-Myers Squibb were worth $14,802,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Modera Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 22.8% in the first quarter. Modera Wealth Management LLC now owns 6,420 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 1,190 shares in the last quarter. Evergreen Capital Management LLC boosted its holdings in Bristol-Myers Squibb by 28.6% in the first quarter. Evergreen Capital Management LLC now owns 11,720 shares of the biopharmaceutical company’s stock worth $741,000 after acquiring an additional 2,605 shares in the last quarter. Flinton Capital Management LLC boosted its holdings in Bristol-Myers Squibb by 19.2% in the first quarter. Flinton Capital Management LLC now owns 37,016 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 5,964 shares in the last quarter. RFG Advisory Group LLC boosted its holdings in Bristol-Myers Squibb by 35.9% in the first quarter. RFG Advisory Group LLC now owns 7,122 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 1,882 shares in the last quarter. Finally, First Republic Investment Management Inc. boosted its holdings in Bristol-Myers Squibb by 17.2% in the first quarter. First Republic Investment Management Inc. now owns 557,192 shares of the biopharmaceutical company’s stock worth $35,243,000 after acquiring an additional 81,856 shares in the last quarter. 71.29% of the stock is owned by institutional investors and hedge funds.

Shares of Bristol-Myers Squibb opened at $52.77 on Monday, MarketBeat.com reports. The firm has a market cap of $86.25 billion, a P/E ratio of 17.53, a price-to-earnings-growth ratio of 1.32 and a beta of 0.99. Bristol-Myers Squibb Co has a 12 month low of $49.96 and a 12 month high of $70.05. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.39 and a current ratio of 1.52.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. The business had revenue of $5.19 billion for the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. Bristol-Myers Squibb’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $0.84 earnings per share. research analysts anticipate that Bristol-Myers Squibb Co will post 3.42 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were issued a dividend of $0.40 per share. The ex-dividend date was Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 3.03%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.

In other Bristol-Myers Squibb news, Director Dinesh C. Paliwal purchased 4,770 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The shares were acquired at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the acquisition, the director now owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.12% of the company’s stock.

Several brokerages have issued reports on BMY. UBS lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 price target on the stock. in a report on Monday, May 21st. ValuEngine lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, April 26th. Barclays dropped their target price on Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating on the stock in a report on Friday, April 27th. Finally, BMO Capital Markets upgraded Bristol-Myers Squibb from an “underperform” rating to a “market perform” rating in a report on Friday, April 27th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $62.84.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply